
Waters Corporation
NYSE-listed analytical instruments company and global leader in liquid chromatography and mass spectrometry, headquartered in Milford, Massachusetts.
Company Type
public
Founded
1958
Headquarters
Milford, Massachusetts, USA
Stock
New York Stock Exchange: WAT
Revenue
$3.17 billion (FY2025); approximately $6.3 billion pro forma including BD business
Employees
approximately 7,900 (pre-combination); approximately 16,000 combined
Primary Market
Global
Shop Waters Corporation Brands
Disclosure: We may earn commission from purchasesAbout Waters Corporation
Is Waters Corporation publicly traded?
Yes. Waters Corporation trades on the New York Stock Exchange under ticker WAT. It went public in November 1995 and is an S&P 500 constituent.
Who founded Waters Corporation?
James Logan Waters founded the company as Waters Associates in 1958 in Framingham, Massachusetts. He was a physicist who had previously worked at Raytheon.
What happened with Waters and BD?
Waters completed a combination with BD's Biosciences and Diagnostic Solutions business on 9 February 2026. The deal valued the BD business at about 18.8 billion dollars, paid BD 4 billion dollars in cash, and gave former BD shareholders 39.2 percent of the combined company.
What does Waters Corporation make?
It makes analytical instruments and consumables, primarily liquid chromatography and mass spectrometry systems, LC columns and chemistry products, the Empower software platform, and thermal analysis instruments under TA Instruments. Post-BD it also makes flow cytometry, molecular diagnostics, and microbiology testing products.
Where is Waters Corporation headquartered?
Waters is headquartered at 34 Maple Street in Milford, Massachusetts, USA, and operates in more than 100 countries.
How much revenue does Waters make?
Waters reported revenue of 3.165 billion dollars for fiscal year 2025. Including the acquired BD business, the combined company has a pro forma revenue base of roughly 6.3 billion dollars.
History of Waters Corporation
James Logan Waters, a physicist who had worked at Raytheon, founded Waters Associates in 1958 in the basement of a Framingham, Massachusetts police station that served as a startup incubator. The company's early work in gel permeation chromatography gave it a founding technology, and through the 1960s and 1970s Waters Associates became the pioneer of high-performance liquid chromatography, commercializing instruments that made HPLC a routine laboratory technique.
Millipore acquired the company in 1980, folding it into a larger laboratory products group. The Waters name and the chromatography franchise survived inside Millipore until 1994, when a management-led buyout took Waters Chromatography independent. The reborn Waters Corporation went public on the New York Stock Exchange in November 1995.
The post-IPO decades were defined by technical innovation and portfolio building. The 2004 launch of ACQUITY Ultra Performance LC, a step-change in separation speed and resolution, reset the industry standard and drove a multi-year instrument replacement cycle. Mass spectrometry grew through successive product generations into a second pillar, and the Empower chromatography data software became the regulated industry's standard platform. TA Instruments, acquired in 1996, added thermal analysis and materials characterization.
Leadership transitioned in the 2010s and 2020s. Douglas Berthiaume ran the company through its growth era before passing to Christopher O'Connell and then, in 2020, to Udit Batra, who arrived from MilliporeSigma with a mandate to push Waters into higher-growth life sciences and diagnostics adjacencies.
The defining move of the Batra era is the BD combination. Announced in July 2025 and completed on 9 February 2026, the transaction spun off BD's Biosciences and Diagnostic Solutions business and merged it into Waters in a Reverse Morris Trust structure. BD received 4 billion dollars in cash, BD shareholders received Waters stock representing 39.2 percent of the combined company, and the acquired business was valued at about 18.8 billion dollars. The combination created four divisions (Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences) and gave Waters a diagnostics platform in molecular, microbiology, and multiplex testing it had previously lacked.
Early integration has not been seamless. Management reported that Q4 2025 revenue for the acquired BD business came in below expectations because of weakened diagnostics demand in China, delayed export approvals during the US federal government shutdown, and a mild flu season that reduced point-of-care testing volumes.
Waters Corporation Sustainability & Ethics
Waters publishes an annual sustainability report covering emissions, waste, water, and product stewardship across its operations. Its 2025 report documents 11 manufacturing facilities, a workforce of about 7,900 operating in more than 100 countries, and environmental programs aligned to SASB, TCFD, and GRI frameworks.
Product-level sustainability centers on instrument efficiency, extended product lifecycles, and chemistry consumables designed to reduce solvent use. The company's products also sit on the positive side of the environmental ledger by enabling customers to test water purity, food safety, and pharmaceutical quality.
As a large public company it is subject to the standard ESG disclosure environment, and its sustainability reporting is self-published rather than third-party certified. No major environmental enforcement action or greenwashing finding is on record against the company as of November 2026.
Controversy, Regulation & Public Scrutiny
Waters' regulatory exposure is operational rather than scandal-driven. The BD integration faces the normal risks of a large merger: execution, retention of acquired commercial teams, regulatory approvals in international markets, and the challenge of separating a business that shares BD's systems, sites, and legal entities during a transition period.
The first post-close quarter highlighted a softer spot: the acquired diagnostics business underperformed expectations in Q4 2025 on weak China demand, export approval delays during the US government shutdown, and a mild flu season. Management has been transparent about the slow start while maintaining the strategic case.
Historically the company has faced periodic patent litigation with Agilent and other instrument competitors, a routine feature of the analytical instruments industry, but no material adverse ruling or regulatory enforcement action is on record as of November 2026.
Brands Owned by Waters Corporation
Waters Corporation owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Waters Corporation
public · Founded 1958 · Milford, Massachusetts, USA
1
brands
Stock Information
Waters Corporation Ownership: Pros & Cons
Advantages
- +Public listing provides capital access, liquidity, and governance transparency
- +Installed-base recurring revenue model produces durable cash flow
- +Duopoly position in premium liquid chromatography gives pricing power
- +BD combination creates a diversified life sciences and diagnostics platform
- +Strong balance sheet and best-in-class margins fund integration and R&D
Considerations
- -BD integration is large relative to legacy scale and carries execution risk
- -Acquired diagnostics business entered with near-term revenue softness
- -Heavy pharmaceutical and life sciences end-market exposure creates cyclical sensitivity
- -Intense competition from Agilent, Thermo Fisher, and Danaher across all divisions
- -Post-deal shareholder base includes a large block of former BD holders with uncertain holding intentions
Frequently Asked Questions About Waters Corporation
Is Waters Corporation publicly traded?
Yes. Waters Corporation trades on the New York Stock Exchange under ticker WAT. It went public in November 1995 and is an S&P 500 constituent.
Who founded Waters Corporation?
James Logan Waters founded the company as Waters Associates in 1958 in Framingham, Massachusetts. He was a physicist who had previously worked at Raytheon.
What happened with Waters and BD?
Waters completed a combination with BD's Biosciences and Diagnostic Solutions business on 9 February 2026. The deal valued the BD business at about 18.8 billion dollars, paid BD 4 billion dollars in cash, and gave former BD shareholders 39.2 percent of the combined company.
What does Waters Corporation make?
It makes analytical instruments and consumables, primarily liquid chromatography and mass spectrometry systems, LC columns and chemistry products, the Empower software platform, and thermal analysis instruments under TA Instruments. Post-BD it also makes flow cytometry, molecular diagnostics, and microbiology testing products.
Where is Waters Corporation headquartered?
Waters is headquartered at 34 Maple Street in Milford, Massachusetts, USA, and operates in more than 100 countries.
How much revenue does Waters make?
Waters reported revenue of 3.165 billion dollars for fiscal year 2025. Including the acquired BD business, the combined company has a pro forma revenue base of roughly 6.3 billion dollars.






